Loading…
Zhejiang maker of vitamin D3 and its derivatives, a major global supplier to supplement and food industries.
Zhejiang maker of vitamin D3 and its derivatives, a major global supplier to supplement and food industries.
Makes vitamin D3 from lanolin, a wax recovered from sheep's wool, and sells it in bulk, so earnings follow D3 prices, which depend on how much the few big producers make. Its calcifediol line (25-hydroxy D3), used in animal feed, is a more specialised product that fetches a higher price per tonne.
In one line: A Chinese vitamin-D3 ingredient supplier.
Moat: narrow (scale, process know-how). One of the world's larger vitamin D3 producers with integrated extraction and synthesis capacity.
Headquarters: Shaoxing, Zhejiang, China · Employees: 1,163
Size Zhejiang Garden Biopharmaceutical (300401.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $983M, the 2330th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.20 on 6 Nov 2026.
Performance Over six months the shares fell 6.5%, against -13.9% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median +6.8%); the operating margin is 23.6% (peer median 8.7%).
Valuation It trades at 24.4× forward earnings against a peer median of 18.7× (5th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points below its cost of capital (8.1% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.27B | CN¥1.23B | CN¥1.24B | CN¥1.09B | CN¥1.41B |
| Revenue growth | — | 0% | +13% | -23% | — |
| Gross profit | CN¥696M | CN¥641M | CN¥679M | CN¥616M | CN¥895M |
| EBITDA | n/a | CN¥536M | CN¥472M | CN¥303M | CN¥458M |
| Net income | CN¥239M | CN¥305M | CN¥309M | CN¥192M | CN¥384M |
| Free cash flow | CN¥131M | CN¥117M | -CN¥13.3M | -CN¥84.6M | -CN¥1.99M |
| Capital expenditure | CN¥319M | CN¥362M | CN¥480M | CN¥245M | CN¥380M |
| Total debt | CN¥1.88B | CN¥2.03B | CN¥2.11B | CN¥2.11B | CN¥884M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Garden Biopharmaceutical 300401.SZ | $983M | -7% | +2% | 24% | 24.4× | 10.2% |
| DSM-Firmenich DSFIR.AS | $29.5B | +62% | -45% | 8% | 30.1× | 24.3% |
| Zhejiang NHU 002001.SZ | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% |
| Basf BAS.DE | $52.6B | +2% | -4% | 7% | 16.8× | 5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300401.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.6% | -4.0% | lowest of 20 |
| 6-month return | -6.5% | -13.9% | 4th highest of 19 |
| Distance from 52-week high | -48.0% | -28.6% | 4th lowest of 21 |
| Revenue growth (TTM) | +2.4% | +6.8% | 7th lowest of 18 |
| Operating margin | 23.6% | 8.7% | 3rd highest of 18 |
| Forward P/E | 24.4× | 18.7× | 5th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 10.2% | 7.1% | 5th most demanding of 11 |
| Growth delivered (Del g) | +13.4% | +8.5% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | -3.2 pp | -0.6 pp | 6th least demanding of 11 |
| ROIC minus cost of capital | -0.1 pp | -1.9 pp | 5th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 24.4× | 10.2% | +13.4% |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 13.0× | 2.1% | -0.5% |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | n/a | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 15.5× | 18.1% | +7.8% |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 12.0× | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | n/a | 8.8% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | n/a | n/a | n/a |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 21.9× | 51.8% | +41.0% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |